| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Peraso Inc.
13D
PRSO · 71360T200
|
20.0% |
11/4/2026
Event 10/28/2026
|
||||
| Nant Capital, LLC | 20.0% | |||||
| Patrick Soon-Shiong | 20.0% | |||||
|
PDS Biotechnology Corporation
13D
PDSB · 70465T107
|
19.9% |
9/21/2026
Event 9/14/2026
|
||||
| Nant Capital, LLC | 19.9% | |||||
| Patrick Soon-Shiong | 19.9% | |||||
|
Panbela Therapeutics, Inc.
13D/A
PBLA · 69833W404
|
87.0% |
4/24/2025
Event 4/22/2025
|
||||
| Nant Capital, LLC | 87.0% | |||||
| Patrick Soon-Shiong | 87.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.